---
title: "Oteracil - Stomach Neoplasms"
sidebar: mydoc_sidebar
permalink: db03209-mesh-d013274-1.html
toc: false 
---


Path ID: `DB03209_MESH_D013274_1`
{% include image.html url="images/db03209-mesh-d013274-1.png" file="db03209-mesh-d013274-1.png" alt="db03209-mesh-d013274-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D010094 | Oteracil | Drug |
| InterPro:IPR023031 | Orotate phosphoribosyltransferase | GeneFamily |
| UBERON:0004786 | Gastrointestinal system mucosa | GrossAnatomicalStructure |
| MESH:D005472 | Fluorouracil | ChemicalSubstance |
| GO:0009636 | Response to toxic substance | BiologicalProcess |
| MESH:D013274 | Stomach neoplasms | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Oteracil | DECREASES ACTIVITY OF | Orotate Phosphoribosyltransferase |
| Orotate Phosphoribosyltransferase | LOCATED IN | Gastrointestinal System Mucosa |
| Gastrointestinal System Mucosa | DECREASES ABUNDANCE OF | Fluorouracil |
| Fluorouracil | AMELIORATES | Response To Toxic Substance |
| Response To Toxic Substance | CORRELATED WITH | Stomach Neoplasms |
|---------|-----------|---------|

Comment: Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy.

Reference: 
  - [https://go.drugbank.com/drugs/DB03209](https://go.drugbank.com/drugs/DB03209)
  - [https://pubchem.ncbi.nlm.nih.gov/compound/Oxonic-Acid#section=Pharmacology-and-Biochemistry](https://pubchem.ncbi.nlm.nih.gov/compound/Oxonic-Acid#section=Pharmacology-and-Biochemistry)
  - [https://en.wikipedia.org/wiki/Tegafur/gimeracil/oteracil](https://en.wikipedia.org/wiki/Tegafur/gimeracil/oteracil)
